Company Profile
Revotar develops innovative anti-inflammatory drugs for inflammatory respiratory indications such as chronic obstructive pulmonary disease (COPD), asthma and acute lung injury (ALI).
The targeted disease areas all provide large markets which are rapidly increasing also due to aging populations and improved diagnoses. The markets for COPD and asthma exceed several billion US$ and existing therapies often do not meet present medical needs. ALI offers additional lucrative commercialization opportunities in high price market segments.
The Company owns the key drug candidate Bimosiamose, the most advanced pan-selectin antagonist. It has already passed several clinical phase I and phase IIa trials e.g. in asthma and COPD with a good safety and efficacy profile in over 300 human beings and over a dozen preclinical in-vivo models. Revotar's pipeline also includes a preclinical program developing anti-inflammatory New Generation compounds.
Revotar’s business strategy as a product-driven company is to advance proprietary, value-added drug products with clinical proof-of-efficacy up to phase IIa in inflammatory diseases, and to commercialize these products through collaboration with selected pharmaceutical companies.
The present revenue strategy of Revotar aims at an early return of investment for shareholders. Out-licensing of projects or partnering in projects generate various opportunities for obtaining revenues through down-payments and milestone compensations.
Revotar Biopharmaceuticals AG is a privately held German company financed by experienced VCs.The company was founded in August 2000.
